STAT

Opinion: Genetic testing: the next big arena for fraud?

The cost of genetic testing for disease assessment can be as high as $10,000. With that kind of money in play, opportunists have seen an opening.

When technology or insurance coverage determinations evolve, so do the opportunities for mischief. That’s what my colleagues and I have been seeing in the genetic testing space.

Genetic testing, whether it’s for ancestral research or assessing disease risk, is an extraordinary tool made possible by advances in science, computing capacity, and the sequencing of the human genome. What was inconceivable 25 years ago can now be accomplished with a saliva sample, some mostly automated laboratory tools, focused computing power, and specialized expertise in the identification of the genetic

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Sanofi Licensing Novavax’s Covid Shot, Moderna’s RSV Vaccine, And More
Sanofi said it has reached a licensing deal to sell Novavax’s Covid shot as well as to try to combine the vaccine with Sanofi’s own flu vaccine.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Pfizer’s DTC Platform, Sandoz’s Feud With A U.K. Trade Group, And More
Pfizer filed a trademark application last month for a website and app providing medical information and mail-order pharmacy and telehealth services to U.S. patients.
STAT1 min read
STAT+: Element Biosciences, An Illumina Rival, On Its Genomics Ambitions — And Why It Hasn’t Gone Public
Element Biosciences' modest growth comes at a time when some other players are struggling in a sequencer market dominated by Illumina.

Related Books & Audiobooks